Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial
Circulation · 2026
DOI: 10.1161/circulationaha.125.077603 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Circulation, 2026. Verfasst von William F Fearon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA (W.F.F., K.T., K.T., A.S., H.I.L., C.A.L., T.H., K…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Coronary Artery Disease, Heart Transplantation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH.
Abstract (Originalsprache)
BACKGROUND: Cardiac allograft vasculopathy is an important cause of mortality after heart transplantation (HT). Dyslipidemia is a major contributor to the development of cardiac allograft vasculopathy. The safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and to prevent cardiac allograft vasculopathy early after HT are not well established. METHODS: In this investigator-initiated, prospective, multicenter, double-blind randomized trial, participants were randomized early after HT to receive either alirocumab or placebo in addition to rosuvastatin. Before randomization and at 1 year, all participants underwent invasive coronary assessment, including angiography, fractional flow reserve, coronary flow reserve, the index of microcirculatory resistance, and intravascular ultrasound with near-infrared spectroscopy. Lipid values were assessed at baseline and at prespecified intervals. The primary end point was the change in coronary artery plaque volume from baseline to 1 year after HT based on serial intravascular ultrasound. RESULTS: A total of 114 HT recipients were included (57 assigned to alirocumab and 57 assigned to placebo). Baseline characteristics were well matched between the 2 groups. The low-density lipoprotein cholesterol levels decreased significantly from baseline to 1 year in the alirocumab arm (72.7±31.7 to 31.5±20.7 mg/dL; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA (W.F.F., K.T., K.T., A.S., H.I.L., C.A.L., T.H., K.S., A.Y., J.W.K., Y.H., J.T., K.K.K.).
- VA Palo Alto Health Care System, CA (W.F.F.).
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands (F.M.Z.).
- Kaiser Permanente, Santa Clara, CA (B.V., C.W.).
- Stanford Diabetes Research Center, Stanford Prevention Research Center, Stanford, CA (J.W.K.).
ORCID-Profile: William F Fearon, Helen I Luikart, Cynthia A Lamendola, Frederik M Zimmermann, Takehiro Hashikata, Kan Saito, Joshua W Knowles, Yasuhiro Honda, Jeffrey Teuteberg, Kiran K Khush
Förderung
- NHLBI NIH HHS
- NIH
Zitieren
APA
Fearon, W. F., Terada, K., Takahashi, K., Skoda, A., Luikart, H. I., Lamendola, C. A., Zimmermann, F. M., Hashikata, T., Saito, K., Yoshida, A., Varr, B., Knowles, J. W., Woo, C., Honda, Y., Teuteberg, J., & Khush, K. K. (2026). Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial. Circulation. https://doi.org/10.1161/circulationaha.125.077603
Vancouver
Fearon WF, Terada K, Takahashi K, Skoda A, Luikart HI, Lamendola CA, et al. Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial. Circulation. 2026. doi:10.1161/circulationaha.125.077603
BibTeX
@article{Fearon2026,
author = {Fearon, William F and Terada, Kosei and Takahashi, Kuniaki and Skoda, Anette and Luikart, Helen I and Lamendola, Cynthia A and Zimmermann, Frederik M and Hashikata, Takehiro and Saito, Kan and Yoshida, Akihiro and Varr, Brandon and Knowles, Joshua W and Woo, Christopher and Honda, Yasuhiro and Teuteberg, Jeffrey and Khush, Kiran K},
title = {Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial},
journal = {Circulation},
year = {2026},
doi = {10.1161/circulationaha.125.077603}
}
EUVIMED